These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 7688883)

  • 41. Dipsogenic effects of excitatory amino acid agonists in pigeons.
    Baron SP; Woods JH
    J Pharmacol Exp Ther; 1993 Feb; 264(2):918-21. PubMed ID: 7679739
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Displacement of excitatory amino acid receptor ligands by acidic oligopeptides.
    Varga V; Janáky R; Marnela KM; Gulyás J; Kontro P; Oja SS
    Neurochem Res; 1989 Dec; 14(12):1223-7. PubMed ID: 2576463
    [TBL] [Abstract][Full Text] [Related]  

  • 43. N-Methyl-D-aspartate and quisqualate/DL-alpha-amino-3-hydroxy-5- methylisoxazole-4-propionic acid receptors: differential regulation by phospholipase C treatment.
    Massicotte G; Kessler M; Lynch G; Baudry M
    Mol Pharmacol; 1990 Feb; 37(2):278-85. PubMed ID: 2154675
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structure-activity studies of 6-(tetrazolylalkyl)-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 1. Effects of stereochemistry, chain length, and chain substitution.
    Ornstein PL; Arnold MB; Allen NK; Bleisch T; Borromeo PS; Lugar CW; Leander JD; Lodge D; Schoepp DD
    J Med Chem; 1996 May; 39(11):2219-31. PubMed ID: 8667365
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Kainic acid binding in human caudate nucleus: effect of Huntington's disease.
    Henke H
    Neurosci Lett; 1979 Oct; 14(2-3):247-51. PubMed ID: 161000
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vintage amino acid meeting describes new tools for amino acid research, subtypes of metabotropic receptors.
    Henley JM; Johnston GA
    Trends Pharmacol Sci; 1991 Oct; 12(10):357-9. PubMed ID: 1662418
    [No Abstract]   [Full Text] [Related]  

  • 47. [Receptive mechanisms of excitatory amino acid signals].
    Yoneda Y
    Yakugaku Zasshi; 1993 Jul; 113(7):469-88. PubMed ID: 7690072
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The hypothalamic lateral tuberal nucleus: normal anatomy and changes in neurological diseases.
    Kremer HP
    Prog Brain Res; 1992; 93():249-61. PubMed ID: 1362279
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease.
    Kremer HP; Roos RA; Dingjan GM; Bots GT; Bruyn GW; Hofman MA
    Neurosci Lett; 1991 Oct; 132(1):101-4. PubMed ID: 1838577
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The absence of unique kainic acid-like molecules in urine, serum, and CSF from Huntington's disease patients.
    Beutler BA; Noronha AB; Poon MM; Arnason BG
    J Neurol Sci; 1981 Sep; 51(3):355-60. PubMed ID: 6115893
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Excitatory amino acids: studies on the biochemical and chemical stability of ibotenic acid and related compounds.
    Nielsen EO; Schousboe A; Hansen SH; Krogsgaard-Larsen P
    J Neurochem; 1985 Sep; 45(3):725-31. PubMed ID: 2863325
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Somatostatin 1-12 immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntington's disease patients.
    Timmers HJ; Swaab DF; van de Nes JA; Kremer HP
    Brain Res; 1996 Jul; 728(2):141-8. PubMed ID: 8864475
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Location, location, location: contrasting roles of synaptic and extrasynaptic NMDA receptors in Huntington's disease.
    Levine MS; Cepeda C; André VM
    Neuron; 2010 Jan; 65(2):145-7. PubMed ID: 20152121
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Do NMDA antagonists prevent neuronal injury? No.
    Buchan AM
    Arch Neurol; 1992 Apr; 49(4):420-1. PubMed ID: 1348413
    [No Abstract]   [Full Text] [Related]  

  • 55. Glutamatergic therapy of Huntington's chorea.
    Giuffra ME; Mouradian MM; Chase TN
    Clin Neuropharmacol; 1992 Apr; 15(2):148-51. PubMed ID: 1350513
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neurotoxicity of folates: implications for vitamin B12 deficiency and Huntington's chorea.
    Brennan MJ; van der Westhuyzen J; Kramer S; Metz J
    Med Hypotheses; 1981 Jul; 7(7):919-29. PubMed ID: 6270515
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Rationale for Hypoxic and Chemical Conditioning in Huntington's Disease.
    Burtscher J; Maglione V; Di Pardo A; Millet GP; Schwarzer C; Zangrandi L
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430140
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Huntington's disease: easing the NMDAR traffic jam.
    Daggett A; Yang XW
    Nat Med; 2013 Aug; 19(8):971-3. PubMed ID: 23921742
    [No Abstract]   [Full Text] [Related]  

  • 59. Weight loss in Huntington's disease.
    Kremer HP; Roos RA
    Arch Neurol; 1992 Apr; 49(4):349. PubMed ID: 1532711
    [No Abstract]   [Full Text] [Related]  

  • 60. Cultured fibroblasts in Huntington's disease. I. Effects of L-glutamic acid.
    Archer FJ; Mancall EL
    Arch Neurol; 1983 Jan; 40(1):19-23. PubMed ID: 6216875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.